Several other research firms have also weighed in on GH. Citigroup cut their target price on shares of Guardant Health from $120.00 to $100.00 in a report on Friday, May 6th. Piper Sandler began coverage on shares of Guardant Health in a research report on Thursday, June 2nd. They issued an overweight rating and a $65.00 target price for the company. Twelve research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of Buy and an average target price of $131.73.
Guardant Health Stock Down 3.6 %
GH opened at $48.38 on Monday. The company has a market capitalization of $4.93 billion, a P/E ratio of -11.74 and a beta of 0.81. The firm’s fifty day moving average price is $43.49 and its two-hundred day moving average price is $55.17. Guardant Health has a fifty-two week low of $27.65 and a fifty-two week high of $133.82. The company has a debt-to-equity ratio of 2.13, a current ratio of 4.87 and a quick ratio of 4.71.
Institutional Trading of Guardant Health
Hedge funds have recently modified their holdings of the stock. Mascoma Wealth Management LLC acquired a new stake in shares of Guardant Health during the 1st quarter worth about $120,000. Guggenheim Capital LLC lifted its stake in shares of Guardant Health by 39.2% during the 4th quarter. Guggenheim Capital LLC now owns 71,741 shares of the company’s stock worth $7,175,000 after buying an additional 20,194 shares during the last quarter. Sofinnova Investments Inc. lifted its stake in shares of Guardant Health by 481.4% during the 4th quarter. Sofinnova Investments Inc. now owns 232,563 shares of the company’s stock worth $23,261,000 after buying an additional 192,563 shares during the last quarter. American Century Companies Inc. lifted its stake in shares of Guardant Health by 56.2% during the 4th quarter. American Century Companies Inc. now owns 1,005,098 shares of the company’s stock worth $100,530,000 after buying an additional 361,498 shares during the last quarter. Finally, Sicart Associates LLC raised its stake in Guardant Health by 219.1% in the 1st quarter. Sicart Associates LLC now owns 133,666 shares of the company’s stock worth $8,854,000 after purchasing an additional 91,783 shares in the last quarter. Institutional investors and hedge funds own 93.69% of the company’s stock.
Guardant Health Company Profile
Guardant Health, Inc, a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients.
- Get a free copy of the StockNews.com research report on Guardant Health (GH)
- MarketBeat Podcast: Find Investing Opportunities For The Rest of 2022
- Deep Value High Yield Newell Brands Is Ready To Bottom
- The Colgate-Palmolive Growth Outlook Brightens
- These Stocks Outperformed Last Time There Was A Recession
- Does Rivian’s Stock Still Have A Future?
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.